Dr. Reddy's Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients
Dr Reddy's Laboratories Ltd
-(DRREDDY)
XNSE:DRREDDY, XBOM:DRREDDY
Dr Reddys Laboratories Ltd Q2FY24; 33% rise in Profits
Dr. Reddy's Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients
Dr. Reddy’s Laboratories (DRREDDY) Q2 FY24 Earnings Concall Transcript
Dr. Reddy's Laboratories ( NSE : DRREDDY) Q2 FY24 Earnings Concall dated Oct. 27, 2023 Corporate Participants: Richa Periwal -- Head Of
Dr Reddy’s Laboratories Ltd Q1FY24; 18% rise in Profits.
Dr. Reddy's Laboratories Ltd is a leading India-based pharamceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients
Dr. Reddy’s Laboratories (DRREDDY) Q4 FY23 Earnings Concall Transcript
Dr. Reddy's Laboratories (NSE:DRREDDY) Q4 FY23 Earnings Concall dated May. 10, 2023. Corporate Participants: Richa Periwal -- Investor Relations G V Prasad -- Co-Chairman and Managing
Dr. Reddy’s Laboratories Q4 FY23 Earnings Conference Call Insights
Key highlights from Dr. Reddy's Laboratories (DRREDDY) Q4 FY23 Earnings Concall Q&A Highlights: [00:21:55] Mikhaila at Barclays asked more details about the
Dr Reddy’s Laboratories Q4 FY23; Net Profit Surged Up To ₹960 Crore
Dr. Reddy’s Laboratories Limited reported Total Income for Q4 FY23 of ₹6,453.7 Crore up from ₹5,596.8 Crore year on year, a growth
Earnings Summary Of Dr Reddy ‘s Laboratories Limited For Q4 FY23
Dr. Reddy's Laboratories Limited is an Indian multinational pharmaceutical company with a presence in over 25 countries. It was founded in 1984
Dr. Reddy’s Laboratories: One Of The Major Player In Generic Segment
“We are progressing well on our pipeline products. The number of filings in several of our key markets have been improving. The
Earnings | Dr. Reddy’s Laboratories Ltd. (NSE:DRREDDY): Q3FY23 Results Out; Total Income rise 27% YoY
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY) is a multinational pharmaceutical company based in Hyderabad, India. The company was founded in 1984 and has
Infographic Ltd.(NSE: DRREDDY) | Q3 FY23 Results | Total Income rises +7.47% qoq
Dr. Reddy's Laboratories (NSE: DRREDDY) is an Indian multinational pharmaceutical company. Founded in 1984, the company primarily develops and sells a wide
Dr. Reddy’s Laboratories Limited Q2FY23; Net Profit Increased By 12%
Dr. Reddy's Laboratories Limited (NSE: DRREDDY) reported Revenue from Operations for Q2 FY23 of ₹63,318 Crore up from ₹57,896 Crore year on
Dr. Reddy’s Laboratories (DRREDDY) Q2 FY23 Earnings Concall Transcript
Dr. Reddy's Laboratories (NSE: DRREDDY) Q2 FY23 Earnings Concall dated Oct. 28, 2022 Corporate Participants: Amit Agarwal -- Head of Investor Relations
Decoding India’s leading API development company – Dr Reddy’s Laboratories
About Company: Founded in 1984 and headquartered in Hyderabad, India, Dr Reddy’s Laboratories (DRL) is India’s second largest pharma company by global
Dr. Reddy’s Laboratories (DRREDDY) FY23 Earnings Concall Transcript
Dr. Reddy's Laboratories (NSE:DRREDDY) FY23 Earnings Concall dated Oct. 13, 2022 Corporate Participants: Francisco Betti -- Head of Shaping the Future of Advanced Manufacturing
Dr Reddy’s Laboratories Ltd. Q1FY23; 6% growth in Revenue
Revenue for Q1 FY23 has increased by 6% YoY to ₹ 52,154 millions. Profits have grown by 108% YoY to ₹ 11,876
Dr. Reddy’s Laboratories (DRREDDY) Q1 FY23 Earnings Concall Transcript
Dr. Reddy's Laboratories (NSE:DRREDDY) Q1 FY23 Earnings Concall dated Jul. 28, 2022 Corporate Participants: Amit Agarwal -- Head of Investor Relations and
Dr. Reddy’s Laboratories (DRREDDY) Q4 FY22 Earnings Concall Transcript
Dr. Reddy's Laboratories (NSE: DRREDDY) Q4 FY22 Earnings Concall dated May 19, 2022 Corporate Participants: Amit Agarwal -- Head of Investor Relations G V
Dr. Reddy’s Laboratories Q3 FY 2022 Research Tear Sheet
Dr. Reddy's Laboratories are an Indian multinational pharmaceutical company. The company is headquartered in Hyderabad, Telangana, India and Princeton, New Jersey, U.S. It was incorporated in
Dr. Reddy’s Laboratories (DRREDDY) Q3 FY22 Earnings Concall Transcript
Dr. Reddy's Laboratories (NSE:DRREDDY) Q3 FY22 Earnings Concall dated Jan. 28, 2022 Corporate Participants: Amit Agarwal -- Head of Investor Relations Parag
Infographic: All you need to know about Dr Reddy’s Labs Q2 performance
Dr. Reddy's Laboratories(NSE:DRREDDY) recently reported its second-quarter 2022 earnings results. The company had a consolidated revenue of ₹5,992 crores with a growth